학술논문
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence
Document Type
article
Author
Lucio Urbani; Nicolò Roffi; Roberto Moretto; Stefano Signori; Riccardo Balestri; Elisabetta Rossi; Piero Colombatto; Gabriella Licitra; Chiara Leoni; Rita Martinelli; Daniele Anacleto Meiattini; Emidio Bonistalli; Beatrice Borelli; Carlotta Antoniotti; Gianluca Masi; Daniele Rossini; Piero Boraschi; Francescamaria Donati; Maria Clotilde Della Pina; Alessandro Lunardi; Francesco Daviddi; Laura Crocetti; Michele Tonerini; Roberto Gigoni; Francesca Quilici; Raffaele Gaeta; Francesca Turco; Adriana Paolicchi; Duccio Volterrani; Vincenzo Nardini; Piero Buccianti; Francesco Forfori; Marco Puccini; Chiara Cremolini
Source
Cancers, Vol 15, Iss 19, p 4683 (2023)
Subject
Language
English
ISSN
2072-6694
Abstract
Background. R0 minor parenchyma-sparing hepatectomy (PSH) is feasible for colorectal liver metastases (CRLM) in contact with hepatic veins (HV) at hepatocaval confluence since HV can be reconstructed, but in the case of contact with the first-order glissonean pedicle (GP), major hepatectomy is mandatory. To pursue an R0 parenchyma-sparing policy, we proposed vessel-guided mesohepatectomy for liver partition (MLP) and eventually combination with liver augmentation techniques for staged major PSH. Methods. We analyzed 15 consecutive vessel-guided MLPs for CRLM at the hepatocaval confluence. Patients had a median of 11 (range: 0–67) lesions with a median diameter of 3.5 cm (range: 0.0–8.0), bilateral in 73% of cases. Results. Grade IIIb or more complications occurred in 13%, median hospital stay was 14 (range: 6–62) days, 90-day mortality was 0%. After a median follow-up of 17.5 months, 1-year OS and RFS were 92% and 62%. In nine (64%) patients, MLP was combined with portal vein embolization (PVE) or ALPPS to perform staged R0 major PSH. Future liver remnant (FLR) volume increased from a median of 15% (range: 7–20%) up to 41% (range: 37–69%). Super-selective PVE was performed in three (33%) patients and enhanced ALPPS (e-ALPPS) in six (66%). In two e-ALPPS an intermediate stage of deportalized liver PSH was necessary to achieve adequate FLR volume. Conclusions. Vessel-guided MLP may transform the liver in a paired organ. In selected cases of multiple bilobar CRLM, to guarantee oncological radicality (R0), major PSH is feasible combining advanced surgical parenchyma sparing with liver augmentation techniques when FLR volume is insufficient.